Riskpilot← Back to searchSign inGet full accessBiomeraki AB
ABActiveOrg 5592977382Vintergatan 4Computer consultancy and computer facilities management activities · NACE 6220Est. 20210 employees
Revenue 2024
SEK 3,5M
+3070% vs 2023
EBITDA margin
-2.4%
+32% vs 2023
Equity ratio
38.9%
Financial strength
Net profit 2024
SEK -100K
+28% vs 2023
| Revenue | SEK 3,5M | +3070% |
| EBITDA | SEK -84K | +32% |
| Net profit | SEK -100K | +28% |
| Total assets | SEK 548K | +657% |
| Equity | SEK 213K | +589% |
| Employees | 0 | — |
Legal name
Biomeraki AB
Org number
5592977382
Legal form
Aktiebolag
NACE code
6220 · Computer consultancy and computer facilities management activities
Founded
20 januari 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder Styrelsen ska bestå av 2 styrelseledamöter och 1 styrelsesuppleant. Registrerad styrelseordförande saknas.
Company purpose
Bolaget skall bedriva produktutveckling, tillverkning och försäljning på internet av kosttillskott och naturläkemedel, samt forskning, studier och utbildning inom kost och egenvård.
Address
Vintergatan 4
Email
elina@biomeraki.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 37 | 111 | 3 517 |
| Staff expenses | — | −513 | −41 | −466 |
| EBITDA | −280 | −629 | −124 | −84 |
| Depreciation & amort. | −4 | −14 | −14 | −14 |
| EBIT | −284 | −643 | −138 | −98 |
| Net financials | — | −3 | −1 | −1 |
| Profit before tax | −284 | −646 | −139 | −100 |
| Tax | −0 | — | — | — |
| Net profit | −284 | −646 | −139 | −100 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 823 | 116 | 72 | 548 |
| Equity | 741 | 95 | 31 | 213 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 82 | 22 | 41 | 335 |
| Total debt | 82 | 22 | 41 | 335 |
EBITDA margin
-2.4%
This company
15.8%
Market median
-115% vs market
20212024
Equity ratio
38.9%
This company
38.2%
Market median
+2% vs market
20212024
Return on equity
-46.7%
This company
18.4%
Market median
-354% vs market
20212024
Net profit margin
-2.8%
This company
8.1%
Market median
-135% vs market
20212024
Asset turnover
6.42×
This company
1.12×
Market median
+473% vs market
20212024
Debt / equity
1.57×
This company
0.62×
Market median
-153% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EA Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2025 | |
| Former (3) | ||
| Chairman | 2025 – 2026 | |
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biomeraki AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Elina Anna Mathilda Wilnerzon | Chief Executive Officer | 0 companies |
| Sami Johannes Kataja | Deputy Board Member | 0 companies |
| Fredrik Evert Ivarsson | Board of Directors | 0 companies |
| Alf Fredrik Litsén | Chairman | 0 companies |
| Johannes Elof Birger Vestman | Board of Directors | 0 companies |
| Therese Erika Vestman | Deputy Board Member | 0 companies |